Inflammatory Nanoparticles Discovered In Joint Fluid of Arthritis
Patients, Based On Methods Pioneered by Nanobac Pharmaceuticals'
Scientists
5/3/2006 11:50:00 AM EST
BIOWIRE
Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company")
today announced that Inflammatory nanoparticles that produce calcified
deposits like those found in arthritic joints have been cultured from
the synovial fluid of rheumatoid arthritis and osteoarthritis patients
by Japanese researchers, as reported in the Journal of Proteome
Research.
"This is the first report to indicate that human synovial fluids
contain Nanobacteria-like particles," the study notes.
The study, Nanobacteria-Like Particles in Human Arthritic Synovial
Fluids, by T. Tsurumoto, T. Matsumoto, A. Yonekura, and H. Shindo,
Department of Orthopaedics, Graduate School of Biomedical Sciences,
Nagasaki University, supports the existence and pathogenic role of
nanobacteria-like particles found in human diseases such as heart,
prostate and kidney disease by Mayo Clinic and other researchers.
In a two year experiment, calcifying nanoparticles were cultured from
the joint fluid of each participating patient, demonstrating that 100
percent of patients had the particles.
The experiment was based on methods pioneered by Nanobac Scientists,
Drs. Neva Ciftcioglu and Olavi Kajander.
"After about 2 months of culture, nanoparticles appeared in the
synovial fluids from all the patients to greater or lesser degrees,"
the study found. "These nanoparticles gradually increased in number and
in size."
Medical researchers have often theorized about the presence of a
calcifying agent that generates associated painful inflammation in
arthritis, but until now had never found one.
Nanobacteria produce a calcium phosphate material known as
calcification, which is shown in many studies, and cited in the Merck
Manual of Diagnosis and Therapy, as provoking inflammation.
"If self-proliferating nanoparticles exist in mammalian synovial fluids
and membranes, then they may have an effect on many joint diseases,"
the study's authors concluded.
"This is another example of independent researchers finding
nanobacteria in patients with a specific disease condition," said
Nanobac Co-Chairman Dr. Benedict Maniscalco, Fellow of the American
College of Cardiology (FACC).
"It shows the value of our research, which is the only work to explain
how calcification occurs in diseases afflicting most of the aging
population," Dr. Maniscalco added.
The findings come on the heels of a paper published in the World
Journal of Urology by Cleveland Clinic researcher Dr. Daniel Shoskes
and Dr. Hadley M. Wood, which concluded that nanobacteria-like
particles may play a ubiquitous role in prostate disease.
Another independent paper published earlier this year in the journal
Urology Research by Khullar et al reports induction of renal
calcification by nanobacteria.
Disclosure statement: Nanobac Pharmaceuticals did not fund the
arthritis or Khullar studies, so the findings are independent.
Link to study abstract at:
http://www.nanobac.com/content/scientific-publications.htm
About Nanobac Pharmaceuticals
Nanobac Pharmaceuticals, Inc. is a life science company dedicated to
the discovery and development of products and services to improve
people's health through the detection and treatment of Calcifying
Nanoparticles, otherwise known as "nanobacteria". The Company's
pioneering research is establishing the pathogenic role of nanobacteria
in soft tissue calcification, particularly in coronary artery,
prostate, and vascular disease.
Nanobac's drug discovery and development is focused on developing new
and existing compounds that effectively inhibit, destroy or neutralize
CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents
for the detection of Calcifying Nanoparticles. IVD products include the
NANOCAPTURE(TM) and NANO-SERO(TM) ELISA assays and the Nano-Vision(TM)
line of antibodies and reagents. Nanobac's BioAnalytical Services works
with biopharmaceutical partners to develop and apply methods for
avoiding, detecting, and inactivating or eliminating CNPs from raw
materials.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For
more information, please visit our website at: http://www.nanobac.com.